Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Eschweiler – page 2

23 clinical trials in Eschweiler, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Eschweiler at a glance
23
clinical trials
  • Not yet recruiting0
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

23 trials in Eschweiler

Open in trial search

Plasma cell myeloma

Not recruiting

Study on Adding Isatuximab to Lenalidomide, Bortezomib, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Study on Abemaciclib and Endocrine Therapy for Patients with Advanced Hormone Receptor Positive HER2 Negative Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Universitaetsklinikum Ulm AöR

Plasma cell myeloma

Not recruiting

Study on Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for Newly Diagnosed High-Risk Multiple Myeloma Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:University Medical Center Hamburg-Eppendorf

Breast cancer+4

Not recruiting

Study Comparing Ribociclib and Endocrine Therapy to Chemotherapy for Patients with Intermediate-Risk HR+/HER2- Early Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ribociclib
  • Sponsor:WSG Women's Cancer Study Group GmbH
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bleomycin Sulfate
  • Sponsor:University Of Cologne

Plasma cell myeloma

Not recruiting

Comparison of intravenous versus subcutaneous isatuximab with lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma patients eligible for transplant

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Universitaetsklinikum Heidelberg AöR

B-cell lymphoma+1

Not recruiting

Study on Epcoritamab, Rituximab, and Lenalidomide for Adults with Untreated Follicular Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Breast cancer+3

Not recruiting

Study on Abemaciclib with Endocrine Therapy for Patients with HR+/HER2- Early Breast Cancer at Intermediate to High Risk

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:WSG Women's Cancer Study Group GmbH

Neoplasm malignant

Not recruiting

Study on Atezolizumab and Chemotherapy for Patients with Triple-Negative Breast Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:NSABP Foundation Inc.

Plasma cell myeloma

Not recruiting

Study on Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone for Multiple Myeloma Patients Not Eligible for Transplant

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:University Of Cologne

Study on Ibrutinib and Drug Combination for Patients with Generalized Mantle Cell Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Ibrutinib
  • Sponsor:Klinikum der Universitaet Muenchen AöR

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Eschweiler

What the registry says about research in the country

01 Breast Cancer Research

Innovative clinical trials focusing on triple-negative breast cancer and HER2-positive breast cancer treatments, evaluating new therapeutic combinations and personalized approaches.

  • Early-stage breast cancer therapies
  • Hormone receptor-positive treatments
  • Neoadjuvant chemotherapy studies

Research includes novel combinations of immunotherapy and targeted treatments to improve patient outcomes.

02 Blood Cancer Studies

Comprehensive research into various blood cancers, including multiple myeloma, lymphoma, and leukemia, testing innovative treatment approaches.

  • Advanced therapy combinations
  • Maintenance treatment strategies
  • Novel drug applications

Trials focus on improving survival rates and developing more effective treatment protocols.

03 Lung Cancer Innovation

Groundbreaking research in non-small cell lung cancer treatment, exploring immunotherapy combinations and targeted therapies.

  • Immunotherapy development
  • Adjuvant treatment studies
  • Disease-free survival assessment

Studies aim to enhance treatment efficacy through innovative drug combinations and personalized approaches.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.